Drug Resistance
Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
Published in Lab Business Week, July 6th, 2008
Forest Laboratories, Inc. (NYSE:FRX) announced positive results from two globally conducted, multi-center Phase III studies of ceftaroline, a broad-spectrum cephalosporin with activity against gram-positive bacteria, such as MRSA and gram negative bacteria, for the treatment of complicated skin and skin structure infections (cSSSI). In both the CANVAS I and CANVAS II studies, ceftaroline as monotherapy achieved the primary endpoint of non-inferiority versus the combination of vancomycin plus aztreonam. Ceftaroline was generally well tolerated. Detailed results are expected to be presented later this year at a medical conference.
"We are extremely pleased with the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2008-07-06)
More Articles from Lab Business Week
- Chromatography
Recent findings in chromatography described by researchers from Consolidated Laboratory Services - Enzyme Research
Report summarizes enzyme research study findings from Cold Spring Harbor Laboratory - Genomma Lab Internacional, S.A.B. de C.V.
Genomma Lab Prices Initial Public Offering and Begins Trading on Mexican Stock Exchange - Life Sciences
Data on life sciences detailed by investigators at Ranbaxy Research Laboratories, Department of Pharmacology - Life Sciences
Scientists at Abbott Laboratories release new data on life sciences - Malaria Therapy
Studies from Wellcome Research Laboratories provide new data on malaria therapy - More from this issue of Lab Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
